KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Goodwill for 14 consecutive years, with $17.2 billion as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Goodwill changed 0.0% year-over-year to $17.2 billion, compared with a TTM value of $17.2 billion through Dec 2023, changed 0.0%, and an annual FY2023 reading of $17.2 billion, changed 0.0% over the prior year.
  • Goodwill was $17.2 billion for Q4 2023 at Teva Pharmaceutical Industries, roughly flat from $17.2 billion in the prior quarter.
  • Across five years, Goodwill topped out at $24.9 billion in Q2 2019 and bottomed at $479.0 million in Q2 2022.
  • Average Goodwill over 5 years is $18.1 billion, with a median of $17.6 billion recorded in 2021.
  • The sharpest move saw Goodwill fell 10.61% in 2019, then changed 0.0% in 2023.
  • Year by year, Goodwill stood at $24.7 billion in 2019, then decreased by 0.68% to $24.5 billion in 2020, then fell by 28.0% to $17.6 billion in 2021, then decreased by 2.59% to $17.2 billion in 2022, then changed by 0.0% to $17.2 billion in 2023.
  • Business Quant data shows Goodwill for TEVA at $17.2 billion in Q4 2023, $17.2 billion in Q4 2022, and $479.0 million in Q2 2022.